Previous 10 | Next 10 |
Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention PR Newswire Dr. Stefanie Johns , Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alz...
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance PR Newswire NEW YORK , March 22, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, ...
Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat Mastocytosis Clinical formulation development of HT-KIT is currently underway. PR Newswire NEW YORK , March 11, 2022 /PR Newswire/ -- Hoth Therapeutics, ...
3 Penny Stocks That Retail Traders Are Watching in March 2022 With another day of trading penny stocks done, there is a lot for investors to consider. One of the most interesting trends happening in the stock market today with penny stocks is the increasing role of retail traders. ...
The shares of development-stage biopharma company, Hoth Therapeutics (HOTH +44.7%) have gained sharply on Thursday after the U.S. Food and Drug Administration (FDA) granted it the Orphan Drug Designation for a potential therapy targeted at mastocytosis. According to the FDA database, the desi...
Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients PR Newswire NEW YORK , Feb. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharma...
Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the trea...
Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ for the treatment of Alzheimer's disease ...
2021 was a year to be easily forgotten for biotech stocks. The S&P 500 climbed 26.9%. However, SPDR S&P Biotech exchange-traded fund dropped 20.5%. Looks like 2022 will be “THE” year for biotech sector. In a recent note from Piper Sandler analyst Christopher Raymond and ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the hottest stocks in the market today is Hoth Therapeutics (NASDAQ: HOTH ). Indeed, HOTH stock has more than doubled on incredible volume today as investors price in a very significant catalyst. Source: luc...
News, Short Squeeze, Breakout and More Instantly...
Hoth Therapeutics Inc. Company Name:
HOTH Stock Symbol:
NASDAQ Market:
Hoth Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment PR Newswire Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitiv...